Alnylam Pharmaceuticals (ALNY) Non-Current Assets (2009 - 2026)

Alnylam Pharmaceuticals' Non-Current Assets history runs 18 years deep, the most recent figure standing at $910.2 million for Q1 2026.

• Quarterly Non-Current Assets fell 3.73% year-over-year to $910.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 billion (up 1.97% YoY) and the FY2025 annual result came in at $915.7 million, down 3.07% from the prior year.
• Non-Current Assets was $910.2 million for Q1 2026 at Alnylam Pharmaceuticals, down from $915.7 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $945.6 million in Q1 2025 and bottomed at $835.8 million in Q1 2024.
• A 5-year average of $875.9 million and a median of $854.1 million in 2022 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2024 — Non-Current Assets dropped 4.73% — and 2025, when it grew 13.13%.
• Alnylam Pharmaceuticals' Non-Current Assets stood at $854.1 million in 2022, then slipped by 0.81% to $847.2 million in 2023, then increased by 11.51% to $944.7 million in 2024, then slipped by 3.07% to $915.7 million in 2025, then declined by 0.59% to $910.2 million in 2026.
• Business Quant data shows ALNY's Non-Current Assets at $910.2 million in Q1 2026, $915.7 million in Q4 2025, and $898.9 million in Q3 2025.